GlassScriptPhysician profile
Shaheen Iqbal
NPI 1194709394
$6,070.63
in general payments reported to CMS, 2019-2025
36 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $1,407 · 2021: $787 · 2022: $11.84 · 2023: $598 · 2024: $787 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,539.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,308.27 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,226.49 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $703.48 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Actelion Pharmaceuticals US, INC. | $369.40 | 2019-2025 | Opsumit, Opsynvi |
| Inspire Medical Systems, INC. | $212.81 | 2023-2024 | Inspire |
| Sunovion Pharmaceuticals INC. | $212.31 | 2019-2020 | |
| Grifols USA, LLC | $187.94 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $159.40 | 2020-2024 | Yupelri |
| Pfizer INC. | $153.28 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $118.60 | 2019-2024 | Dupixent |
| Viatris Specialty LLC | $108.80 | 2025 | Yupelri |
| United Therapeutics Corporation | $105.95 | 2021-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $101.15 | 2021-2025 | Smartvest |
| Axsome Therapeutics, INC. | $93.44 | 2024-2025 | Sunosi |
| Genzyme Corporation | $92.30 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $90.13 | 2021-2024 | |
| Insmed, INC. | $89.43 | 2019-2025 | Arikayce |
| Verona Pharma, INC. | $86.48 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $85.51 | 2024-2025 | Glassia |
| Intuitive Surgical, INC. | $71.85 | 2024 | |
| Mallinckrodt Hospital Products INC. | $63.36 | 2021-2024 | Acthar |
| Teva Pharmaceuticals USA, INC. | $59.71 | 2019-2021 | |
| Amgen INC. | $56.82 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $47.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $40.79 | 2019-2020 | |
| Baxter Healthcare | $34.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $33.59 | 2020-2023 | |
| Philips North America LLC | $32.73 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $21.72 | 2024 | Lumryz |
| Advanced Respiratory, INC | $21.59 | 2020 | |
| Novo Nordisk INC | $18.50 | 2025 | Wegovy |
| Resmed Corp | $15.06 | 2019 | |
| Astellas Pharma US INC | $14.75 | 2021 | |
| Gilead Sciences, INC. | $11.94 | 2021 | |
| Fisher & Paykel Healthcare INC | $11.38 | 2019 | |
| Biomerieux INC | $9.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaheen Iqbal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.